Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 14Sarcoma 11Glioblastoma 11Squamous Cell Carcinoma of Head and Neck 10Rectal Neoplasms 8Esophageal Neoplasms 8Stomach Neoplasms 7Urinary Bladder Neoplasms 6Neoplasms 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Brain Neoplasms 5Oropharyngeal Neoplasms 4Lung Neoplasms 4Hypopharyngeal Neoplasms 4Head and Neck Neoplasms 4Glioma 4Colonic Neoplasms 4Recurrence 3Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Astrocytoma 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Skin Neoplasms 2

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Surgical Procedures, Operative × 1 year × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡